Alpha Lipoic Acid Effect on No-Reflow Phenomenon

• Status: Not yet recruiting
• Trial end date: 2023-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of No-Reflow in post myocardial infarction (MI) patients by assessment of aldehyde dehydrogenase-2 (ALDH2) as a marker of oxidative stress and paraoxonase-1 (PON-1) as a marker of oxidative stress and inflammation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Thioctic Acid

Criteria

Inclusion Criteria:

1. Female or male aged >18 and < 75 years

2. STEMI patients undergoing PCI

Exclusion Criteria:

1. Patients with a recent history of myocardial infarction (MI), a previous PCI or a previous coronary artery bypass graft

2. A late presentation (>12 h), unsuccessful primary PCI (residual stenosis >50% in the culprit lesion after procedure)

3. Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI

4. Infectious or inflammatory disease

5. Severe liver or renal disease, (AST or ALT >3x ULN or Total bilirubin >2.5 x ULN), (CrCl < 60 ml/min (based on the Cockroft-Gault equation)

6. Neoplasm, or hematological disorders

7. Pregnant or breast-feeding patients

8. Active participation in another clinical study

9. Patients taking Alpha Lipoic Acid.